MADISON, Wis., March 6, 2018 /PRNewswire/ -- Exact Sciences
Corp. (Nasdaq: EXAS) today announced that Paul J. Limburg, M.D., M.P.H., has been
appointed the company's co-chief medical officer. Dr. Limburg is a
gastroenterologist and a professor of medicine at Mayo Clinic. He
is also a co-leader of the Cancer Prevention and Control program
within Mayo Clinic Cancer Center.
"We are delighted to welcome Dr. Limburg and believe he'll play
a critical leadership role in our mission to eradicate colon
cancer," said Kevin T. Conroy,
chairman and CEO of Exact Sciences. "Dr. Limburg's valuable mix of
cancer prevention experience in both the clinical and scientific
research arenas will provide a great advantage to our company.
He'll also guide the expansion of our relationships with key
opinion leaders and institutions in the cancer community."
While at Mayo Clinic, Dr. Limburg has served as medical director
of Mayo Clinic Global Business Solutions (GBS), which delivers
products and services that extend Mayo Clinic's specialized
clinical knowledge and expertise worldwide. Dr. Limburg also served
as medical director of several of Mayo Clinic's health and
well-being programs.
Dr. Limburg's extensive research and clinical experience with
gastrointestinal cancer makes him well suited to advise Exact
Sciences where he will assess research opportunities to inform,
expand and accelerate the adoption of effective colon cancer
screening options such as Cologuard. He will continue to serve as a
gastroenterologist with Mayo Clinic's Division of Gastroenterology
and Hepatology, co-leader of the Cancer Prevention and Control
program within Mayo Clinic Cancer Center, and principal
investigator for the NCI-funded cancer prevention network clinical
trials consortium. He is a medical advisory board member of Fight
Colorectal Cancer, a patient education and advocacy group.
"I am excited to join the outstanding team at Exact Sciences
that is already making extraordinary progress toward its mission of
fighting colon cancer through early detection," Dr. Limburg said.
"Colorectal cancer is highly preventable with proper screening, yet
millions of adult Americans are not being screened as recommended.
As a result, colon cancer has remained the second leading
cancer killer in the U.S. The company's Cologuard colon cancer
screening test was developed in collaboration with Mayo Clinic and
has built a strong reputation in both the patient and healthcare
provider communities because of its simplicity, accuracy and
effectiveness. I look forward to working with the team at Exact
Sciences to continue to expand the adoption of Cologuard and to
offer guidance in building out the company's cancer detection test
portfolio."
Dr. Limburg earned a Bachelor of Arts in chemistry from
Augustana College, a Doctor of Medicine
from Mayo Medical School, and Master of Public Health from the
Johns Hopkins School of Hygiene and Public Health. He completed his
internal medicine residency and gastroenterology and hepatology
fellowship training at the Mayo Graduate
School of Medicine. Dr. Limburg also completed an
advanced fellowship in preventive oncology at the National Cancer
Institute.
Mayo Clinic and Dr. Limburg have a financial interest in the
technology referenced in this news release. Mayo Clinic will use
any revenue it receives to support its not-for-profit mission in
patient care, education and research.
About Cologuard
Cologuard was approved by the FDA in
August 2014 and results from Exact
Sciences' prospective 90-site, point-in-time, 10,000-patient
pivotal trial were published in the New England Journal of Medicine
in March 2014. Cologuard is included
in the American Cancer Society's (2014) colorectal cancer screening
guidelines and the recommendations of the U.S. Preventive Services
Task Force (2016) and National Comprehensive Cancer Network (2016).
Cologuard is indicated to screen adults of either sex, 50 years or
older, who are at average risk for colorectal cancer. Cologuard is
not for everyone and is not a replacement for diagnostic
colonoscopy or surveillance colonoscopy in high-risk individuals.
False positives and false negatives do occur. Any positive test
result should be followed by a diagnostic colonoscopy. Following a
negative result, patients should continue participating in a
screening program at an interval and with a method appropriate for
the individual patient. Cologuard performance when used for repeat
testing has not been evaluated or established. For more information
about Cologuard, visit www.cologuardtest.com. Rx Only.
About Exact Sciences Corp.
Exact Sciences
Corp. is a molecular diagnostics company focused on the early
detection and prevention of the deadliest forms of cancer. The
company has exclusive intellectual property protecting its
non-invasive, molecular screening technology for the detection of
colorectal cancer. For more information, please visit the company's
website at www.exactsciences.com, follow Exact
Sciences on Twitter @ExactSciences or find Exact
Sciences on Facebook.
Safe Harbor Statement
This news release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, that are intended to
be covered by the "safe harbor" created by those sections.
Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can
generally be identified by the use of forward-looking terms such as
"believe," "expect," "may," "will," "should," "would," "could,"
"seek," "intend," "plan," "goal," "project," "estimate,"
"anticipate" or other comparable terms. All statements other than
statements of historical facts included in this news release
regarding our strategies, prospects, financial condition,
operations, costs, plans and objectives are forward-looking
statements. Examples of forward-looking statements include, among
others, statements we make regarding expected future operating
results, anticipated results of our sales and marketing efforts,
expectations concerning payer reimbursement and the anticipated
results of our product development efforts. Forward-looking
statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current beliefs,
expectations and assumptions regarding the future of our business,
future plans and strategies, projections, anticipated events and
trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
are difficult to predict and many of which are outside of our
control. Our actual results and financial condition may differ
materially from those indicated in the forward-looking statements.
Therefore, you should not rely on any of these forward-looking
statements. Important factors that could cause our actual results
and financial condition to differ materially from those indicated
in the forward-looking statements include, among others, the
following: our ability to successfully and profitably market our
products and services; the acceptance of our products and services
by patients and healthcare providers; our ability to meet demand
for our products and services; the willingness of health insurance
companies and other payers to cover Cologuard and adequately
reimburse us for our performance of the Cologuard test; the amount
and nature of competition from other cancer screening and
diagnostic products and services; the effects of the adoption,
modification or repeal of any healthcare reform law, rule, order,
interpretation or policy; the effects of changes in pricing,
coverage and reimbursement for our products and services, including
without limitation as a result of the Protecting Access to Medicare
Act of 2014; recommendations, guidelines and quality metrics issued
by various organizations such as the U.S. Preventive Services Task
Force, the American Cancer Society, and the National Committee for
Quality Assurance regarding cancer screening or our products and
services; our ability to successfully develop new products and
services; our success establishing and maintaining collaborative,
licensing and supplier arrangements; our ability to maintain
regulatory approvals and comply with applicable regulations; and
the other risks and uncertainties described in the Risk Factors and
in Management's Discussion and Analysis of Financial Condition and
Results of Operations sections of our most recently filed Annual
Report on Form 10-K and our subsequently filed Quarterly Reports on
Form 10-Q. We undertake no obligation to publicly update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Contact
J.P. Fielder
Exact Sciences Corp.
jpfielder@exactsciences.com
608-210-5220
View original content with
multimedia:http://www.prnewswire.com/news-releases/mayo-clinics-dr-paul-limburg-to-join-exact-sciences-medical-leadership-300608540.html
SOURCE EXACT SCIENCES CORP